Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM8JQZC)

Drug Name
BNZ-1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cutaneous T-cell lymphoma 2B01 Phase 2 [1]
T-cell leukaemia 2A90 Phase 2 [2]
Large granular lymphocytic leukemia 2A90.1 Phase 1/2 [3]
Cross-matching ID
TTD Drug ID
DM8JQZC

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-15 (IL15) TTJFA35 IL15_HUMAN Inhibitor [4]
Interleukin-2 (IL2) TTF89GD IL2_HUMAN Inhibitor [4]
Interleukin-9 (IL9) TT0JTFD IL9_HUMAN Inhibitor [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-15 (IL15) DTT IL15 4.678 5.178 4.986 5.938
Interleukin-2 (IL2) DTT IL2 0.848 4.548 3.548 4.053
Interleukin-9 (IL9) DTT IL9 2.35 1.766 2.104 1.926
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cutaneous T-cell lymphoma
ICD Disease Classification 2B01
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-2 (IL2) DTT IL2 7.64E-01 1.04E-02 0.07
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT03239392) A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of Bioniz Therapeutics.